article thumbnail

US FDA approves Pfizer’s migraine nasal spray Zavzpret

Pharmaceutical Technology

The company stated that the regulatory approval expands its migraine portfolio, which includes oral therapy for acute and preventive treatment. The company expects to launch Zavzpret in pharmacies in July.

article thumbnail

New test reveals existing antibiotics, hiding in plain sight on pharmacy shelves, can cure superbugs

Medical Xpress

A new test revealed that FDA-approved antibiotics—available at your neighborhood pharmacy—can effectively treat superbugs. They are not prescribed, however, because the gold-standard test predicts they will not work.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ogsiveo Receives FDA Approval as First Therapy for Desmoid Tumors

XTalks

Pfizer spinout SpringWorks Therapeutics’ Ogsiveo (nirogacestat) has received US Food and Drug Administration (FDA) approval for the treatment of desmoid tumors, an ultra-rare subtype of non-cancerous soft tissue sarcomas that can cause severe pain and disfigurement.

article thumbnail

GSK stays a step ahead in RSV vaccine battle as Arexvy becomes available at US pharmacies

Fierce Pharma

company was first to secure FDA approval for its shot Arexvy for adults 60 and older, beating out rivals from Pfizer and Moderna. retail pharmacies, the company said. . | As companies have flocked to compete in the new respiratory syncytial virus (RSV) vaccine market, GSK has had the best timing. In May, the U.K.

article thumbnail

The FDA Just Approved The First Fast-Acting Nasal Spray For Migraines

AuroBlog - Aurous Healthcare Clinical Trials blog

The US Food and Drug Administration has approved a fast-acting nasal spray from Pfizer designed to treat migraines, the US pharmaceutical giant said Friday.

article thumbnail

Konvomep Gets FDA Approval as a New Oral Liquid Formulation Option of Omeprazole

XTalks

On Friday, Azurity Pharmaceuticals announced that the US Food and Drug Administration (FDA) approved their innovative oral liquid formulation Konvomep (omeprazole and sodium bicarbonate for oral suspension). John’s University College of Pharmacy & Health Sciences, Queens, New York.

article thumbnail

FDA Approves Zoryve Topical Foam for Seborrheic Dermatitis

Pharmaceutical Commerce

Arcutis Biotherapeutics said Zoryve foam will be widely available via key wholesaler and dermatology pharmacy channels by the end of January 2024.